Flexible-Dose Pilot Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD
Post-Traumatic Stress Disorder
Enrolment: 40 · Results not recorded
Loading the evidence…
Drug · Centrally acting analgesic: weak mu-opioid receptor agonist (ChEMBL mec_id 707, AGONIST, FDA label ref) with additional serotonin and noradrenaline reuptake inhibition not captured in the ChEMBL MoA table. Active O-desmethyl metabolite (M1) carries most opioid activity. ATC N02AX02. Black box warning.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Post-Traumatic Stress Disorder
Enrolment: 40 · Results not recorded
Postoperative Delirium
Enrolment: 40 · Results not recorded
Chronic Pain
Enrolment: 650 · Results not recorded
COVID-19
Enrolment: 100 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Laminectomy and spinal cord injury at the eighth thoracic vertebra
Tramadol did not alter locomotor recovery at any time point, although it lowered pain scores on postoperative days 1, 3 and 7.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Acute hindlimb ischaemia by left femoral artery clamping for 3 h followed by 3 h reperfusion, with assessment of remote myocardial injury
Tramadol preserved superoxide dismutase, catalase and glutathione peroxidase levels (p<0.05 versus ischaemia-reperfusion alone), prevented the rise in myocardial malondialdehyde and significantly reduced the total histopathological injury score.
Extraction: extract · Subtype source: review · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.